Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model

<p>Abstract</p> <p>Background</p> <p>There is strong evidence demonstrating that activation of epidermal growth factor receptors (EGFRs) leads to tumor growth, progression, invasion and metastasis. Erlotinib and gefitinib, two EGFR-targeted agents, have been shown to be...

Full description

Bibliographic Details
Main Authors: Collantes Maria, Peñuelas Ivan, Catena Raul, Redrado Miriam, Manrique Irene, Perez-Stable Carlos, Parrondo Ricardo, Nguewa Paul A, Diaz Roque, Díaz-González Juan, Calvo Alfonso
Format: Article
Language:English
Published: BMC 2010-05-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/188

Internet

http://www.biomedcentral.com/1471-2407/10/188

Similar Items